封面
市场调查报告书
商品编码
1543628

製药和生物技术领域的合资交易(2016-2024)

Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2024

出版日期: | 出版商: Current Partnering | 英文 250+ Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告深入了解并分析公司如何以及为何进行合资交易。

本报告提供了2016年至2024年合资计画的详细资讯。

本报告提供了双方宣布的合资交易的付款条款的资讯。这些资料提供了有关支付条款和其他交易条款的宝贵见解。

了解潜在合作伙伴谈判条款的弹性,并深入了解谈判过程,以了解条款谈判期间的预期结果。许多小型企业会要求提供付款条件的详细信息,但在包括付款方式和权利如何转让时,细节是关键。

本报告提供了当前协议交易/合作资料库中记录的自2016年以来宣布的合资交易的完整列表,包括可用的财务条款的连结。

主要优点

本报告为读者提供了以下主要好处:

  • 了解2016年以来的交易完成趋势
  • 查看合资企业交易
  • 基准分析:确定交易的市场价值
  • 财务状况
  • 交易清单:依公司名称(A-Z)、依治疗领域、依技术类型
  • 主要交易(金额基础)
  • 最活跃的交易撮合者
  • 每笔交易的资产识别和交易条件
  • 取得合约文件:深入了解交易结构
  • 实质审查:评估拟议交易条款对合作伙伴公司的适用性
  • 节省数百小时的研究时间

调查范围

  • 本报告目的是详细了解全球领先的生物创业公司之间的合资趋势和交易结构。

此报告包含以下资讯:

  • 生物製药产业合资交易趋势
  • 合资企业交易架构:概述
  • 製药和生技产业的合资交易记录列表
  • 主要合资交易(价值基础)
  • 最活跃的合资企业交易者
  • 合资企业的主要合作伙伴资源

此报告列出了可获得资讯的交易:

  • 依公司名称(A-Z)
  • 依交易金额
  • 依治疗领域
  • 依技术型
  • 每个交易标题都透过网路连结连结到实际交易记录的线上版本。
  • 此报告提供了对许可协议的可用合约文件的全面存取。

此报告列出了可获得资讯的交易:

  • 公司AZ
  • 标题数量
  • 治疗领域
  • 技术类型
  • 每个交易标题都透过网路连结连结到实际交易记录的线上版本,可以轻鬆存取每个合约文件(如果有)。
  • 此报告提供对合资企业交易的可用记录的全面存取。

合约分析允许实质审查:

  • 授予和选择了哪些权利?
  • 合约授予了哪些权利?
  • 授予哪些专有权?
  • 合约的付款结构是怎样的?
  • 如何审核销售和付款?
  • 合约期限是多久?
  • 合约的主要条款是如何定义的?
  • 如何对待和拥有知识产权?
  • 谁负责商业化?
  • 谁负责开发、供应和製造?
  • 如何管理保密和发布?
  • 如何解决争议?
  • 什么情况下可以取消合约?
  • 如果所有者发生变化会怎样?
  • 已就何种类型的分授权或分包条款达成协议?
  • 公司需要哪些样板条款?
  • 哪些样板条款会根据合作伙伴和交易类型的不同而有所不同?
  • 每家公司都主张合约法中的哪一个管辖权?

目录

执行摘要

第1章 简介

第2章 合资趋势

  • 简介
  • 合资协议的定义
  • 合资企业的趋势(2016年以来)
    • 签署合资交易:依年份(2016-2024年)
    • 签署合资交易:依发展阶段(2016-2024年)
    • 签署合资交易:依行业分类(2016-2024年)
    • 签署合资交易:依治疗领域(2016-2024年)
    • 签署合资交易:依技术类型(2016-2024年)
    • 签署合资交易:针对最活跃的公司(2016-2024年)
  • 签订合资伙伴关係协议的原因
  • 未来的合资企业

第3章 合资交易结构概述

  • 简介
  • 合资协议的结构

第4章 重大合营交易

  • 简介
  • 主要合资交易(价值基础)

第5章 25 家最活跃合资企业交易者

  • 简介
  • 最活跃的25 家合资企业交易者

第6章 合资交易清单(含合约明细)

  • 简介
  • 合资交易协议(2016-2024)
  • 交易清单
  • 交易清单:合资企业交易协议,依公司名称(A-Z)
  • 交易清单:合资企业交易,依治疗领域
  • 交易清单:合资企业交易,依技术类型

关于Wildwood Ventures

  • 目前的合作关係
  • 当前合约
  • Current Partnering的最新报告标题
简介目录
Product Code: CP2060

Joint Venture Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Fully revised and updated, the report provides details of joint venture deals from 2016 to 2024.

The report provides access to joint venture deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of joint venture deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of joint venture dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of joint venture deals.

Chapter 4 provides a review of the leading joint venture deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the joint venture deal.

The deal directory includes a comprehensive listing of all joint venture deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in joint venture dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about joint venture alliances.

Key benefits

Joint Venture Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse joint venture deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Joint Venture Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading biopharma companies worldwide.

Joint Venture Deals in Pharmaceuticals and Biotechnology includes:

  • Trends in joint venture dealmaking in the biopharma industry
  • Overview of joint venture deal structure
  • Directory of joint venture deal records covering pharmaceutical and biotechnology
  • The leading joint venture deals by value
  • Most active joint venture dealmakers
  • The leading joint venture partnering resources

In Joint Venture Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
  • Joint Venture Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for joint venture deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the rights granted or optioned?
  • What rights are granted by the agreement?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are intellectual property rights handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in joint venture dealmaking

  • 2.1. Introduction
  • 2.2. Definition of joint venture deal
  • 2.3. Trends in joint venture deals since 2016
    • 2.3.1. Joint venture dealmaking by year, 2016-2024
    • 2.3.2. Joint venture dealmaking by phase of development, 2016-2024
    • 2.3.3. Joint venture dealmaking by industry sector, 2016-2024
    • 2.3.4. Joint venture dealmaking by therapy area, 2016-2024
    • 2.3.5. Joint venture dealmaking by technology type, 2016-2024
    • 2.3.6. Joint venture dealmaking by most active company, 2016-2024
  • 2.4. Reasons for entering into joint venture partnering deals
  • 2.5. The future of joint venture deals

Chapter 3 - Overview of joint venture deal structure

  • 3.1. Introduction
  • 3.2. Joint venture agreement structure

Chapter 4 - Leading joint venture deals

  • 4.1. Introduction
  • 4.2. Top joint venture deals by value

Chapter 5 - Top 25 most active joint venture dealmakers

  • 5.1. Introduction
  • 5.2. Top 25 most active joint venture dealmakers

Chapter 6 - Joint venture deals including contracts directory

  • 6.1. Introduction
  • 6.2. Joint venture deals with contracts 2016-2024
  • Deal directory
  • Deal directory - joint venture dealmaking by companies A-Z
  • Deal directory - joint venture dealmaking by therapy area
  • Deal directory - joint venture dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES

  • Figure 1: Definition of joint venture deal
  • Figure 2: Trends in joint venture deal announcements, 2016-2024
  • Figure 3: Joint venture deals signed at each phase of development, 2016-2024
  • Figure 4: Joint venture deals by industry sector, 2016-2024
  • Figure 5: Joint venture deals by therapy area, 2016-2024
  • Figure 6: Joint venture deals by technology type, 2016-2024
  • Figure 7: Top 25 most active joint venture dealmakers, 2016-2024
  • Figure 8: Top joint venture deals by value, 2016-2024
  • Figure 9: Most active joint venture dealmakers, 2016-2024